A
Angelo M. De Marzo
Researcher at Johns Hopkins University School of Medicine
Publications - 401
Citations - 39287
Angelo M. De Marzo is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Prostate cancer & Prostate. The author has an hindex of 98, co-authored 368 publications receiving 34888 citations. Previous affiliations of Angelo M. De Marzo include Johns Hopkins University & University of Amsterdam.
Papers
More filters
Journal Article
Overexpression of Hypoxia-inducible Factor 1α in Common Human Cancers and Their Metastases
Hua Zhong,Angelo M. De Marzo,Erik Laughner,Michael Lim,David A Hilton,David Zagzag,Peter Buechler,William B. Isaacs,Gregg L. Semenza,Jonathan W. Simons +9 more
TL;DR: The first clinical data indicating that HIF-1alpha may play an important role in human cancer progression are provided, indicating adaptations to a hypoxic microenvironment that are correlated with tumor invasion, metastasis, and lethality.
Journal ArticleDOI
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.
Emmanuel S. Antonarakis,Changxue Lu,Hao Wang,Brandon Luber,Mary Nakazawa,Jeffrey C. Roeser,Yan Chen,Tabrez A. Mohammad,Yi Chen,Helen L. Fedor,Tamara L. Lotan,Qizhi Zheng,Angelo M. De Marzo,John T. Isaacs,William B. Isaacs,Rosa Nadal,Channing J. Paller,Samuel R. Denmeade,Michael A. Carducci,Mario A. Eisenberger,Jun Luo +20 more
TL;DR: In this article, the androgen-receptor splice variant 7 (AR-V7) was found to be associated with resistance to enzalutamide and abiraterone.
Journal ArticleDOI
c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism.
Ping Gao,Irina Tchernyshyov,Tsung Cheng Chang,Yun-Sil Lee,Kayoko Kita,Takafumi Ochi,Karen I. Zeller,Angelo M. De Marzo,Jennifer E. Van Eyk,Joshua T. Mendell,Chi V. Dang +10 more
TL;DR: In this paper, the c-Myc (hereafter referred to as Myc) oncogenic transcription factor, which is known to regulate microRNAs and stimulate cell proliferation, transcriptionally represses miR-23a and miR23b, resulting in greater expression of their target protein, mitochondrial glutaminase, in human P-493 B lymphoma cells and PC3 prostate cancer cells.
Journal ArticleDOI
Inflammation in prostate carcinogenesis
Angelo M. De Marzo,Angelo M. De Marzo,Elizabeth A. Platz,Siobhan Sutcliffe,Jianfeng Xu,Henrik Grönberg,Charles G. Drake,Yasutomo Nakai,William B. Isaacs,William G. Nelson +9 more
TL;DR: Whether prostate cancer is driven by inflammation, and if so, to develop new strategies to prevent the disease, is determined by developing new experimental animal models coupled with classical Epidemiological studies, genetic epidemiological studies and molecular pathological approaches.
Journal Article
Abstract #LB-186: c-Myc suppression of miR-23 enhances mitochondrial glutaminase and glutamine metabolism
Ping Gao,Irina Tchernyshyov,Tsung Cheng Chang,Yun Sil Lee,Kayoko Kita,Takafumi Ochi,Karen I. Zeller,Angelo M. De Marzo,Jennifer E. Van Eyk,Joshua T. Mendell,Chi Dang +10 more
TL;DR: The c-Myc oncogenic transcription factor, which is known to regulate microRNAs and stimulate cell proliferation, transcriptionally represses miR-23a and miB-23b, resulting in greater expression of their target protein, mitochondrial glutaminase, in human P-493 B lymphoma cells and PC3 prostate cancer cells, which leads to upregulation of glutamine catabolism.